T790米
医学
吉非替尼
阿法替尼
埃罗替尼
肺癌
肿瘤科
表皮生长因子受体抑制剂
内科学
抗性突变
奥西默替尼
癌症
表皮生长因子受体
癌症研究
生物
生物化学
逆转录酶
基因
核糖核酸
作者
Zofia Piotrowska,Lecia V. Sequist
出处
期刊:JAMA Oncology
[American Medical Association]
日期:2016-07-01
卷期号:2 (7): 948-948
被引量:30
标识
DOI:10.1001/jamaoncol.2016.0333
摘要
Importance
Patients withEGFR-mutant lung cancer benefit from treatment with EGFR inhibitors such as erlotinib, gefitinib, and afatinib, but outcomes are limited by the eventual development of resistance to these agents. Over half of patients acquire a secondary T790M mutation inEGFRat the time of progression and a substantial minority develops resistance through other mechanisms. Multiple treatment strategies are now available to patients whose disease has progressed on their initial EGFR inhibitor, including therapies targeting both T790M, and non–T790M-mediated resistance. Observations
This review summarizes information about and current treatment strategies for patients withEGFR-mutant lung cancer whose disease progresses on their initial EGFR inhibitor, including those with T790M and other types of acquired resistance. Postprogression therapy should be tailored based on identified resistance mechanisms, sites, and pace of disease progression, and patient preference. Biopsy and genotyping of resistant tissue or plasma are essential to identifying resistance mechanisms and selecting the most appropriate treatment when patients’ disease progresses during treatment with an initial EGFR inhibitor. Third-generation EGFR inhibitors are generally preferred for patients with T790M-positive resistance, whereas standard chemotherapy and clinical trials are preferred for those without T790M. For select patients, treatment can be continued beyond progression and local ablative therapies can be used to target sites of oligoprogression. Conclusions and Relevance
Treatment for patients who progress on their initial EGFR inhibitor should be tailored to identified resistance mechanisms and sites of progression. Emerging reports about resistance to third-generation EGFR inhibitors will lay the groundwork for overcoming the next generation of resistance, and further research is needed to develop more effective therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI